Drug Interactions between Fotivda and venetoclax
This report displays the potential drug interactions for the following 2 drugs:
- Fotivda (tivozanib)
- venetoclax
Interactions between your drugs
venetoclax tivozanib
Applies to: venetoclax and Fotivda (tivozanib)
Consumer information for this interaction is not currently available.
MONITOR: Coadministration with inhibitors of breast cancer resistance protein (BCRP) may increase the plasma concentrations of venetoclax, which is a substrate of this efflux transporter. In a study of 11 previously treated non-Hodgkin lymphoma patients, when the potent CYP450 3A4 inhibitor, P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) inhibitor ketoconazole (400 mg daily for 7 days) was coadministered with venetoclax (50 mg single dose), venetoclax peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 2.3-fold and 6.4-fold, respectively. However, data are not available for sole BCRP inhibitors. Increased venetoclax exposure may potentiate the risk of tumor lysis syndrome, particularly at initiation of therapy and during the dosage ramp-up phase, as well as other adverse effects such as diarrhea, nausea, vomiting, neutropenia, anemia, and thrombocytopenia.
MANAGEMENT: Caution and closer monitoring should be considered if venetoclax is used concomitantly with BCRP inhibitors. Some authorities advise that their coadministration should generally be avoided when venetoclax therapy is initiated and during its dosage titration phase, regardless of indication. If coadministration is required, patients should be monitored closely for signs and symptoms of venetoclax-related adverse effects and the dosage modified as per the manufacturer's recommendations.
Drug and food interactions
venetoclax food
Applies to: venetoclax
Food helps to increase the absorption of venetoclax. You should take each dose of venetoclax with a meal and water at approximately the same time each day. Do not consume grapefruit, grapefruit juice, Seville oranges, or starfruit during treatment with venetoclax. Doing so can significantly increase blood levels and effects of the medication. This may increase your risk of developing tumor lysis syndrome, a serious condition that is caused by the rapid breakdown of cancer cells and that can lead to kidney failure and even death. In addition, you may be more likely to experience other side effects such as nausea; vomiting; diarrhea; fatigue; and impaired bone marrow function resulting in low numbers of different types of blood cells, which can increase the risk of anemia, bleeding problems, and infections. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.